Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients With Type 1 Diabetes
Source : https://pubmed.ncbi.nlm.nih.gov/38512447/
In this pilot (off-label) study, we conclude that tirzepatide facilitated an average 18.5% weight loss (>46 pounds) and improved glucose control in OW/OB patients with T1D at one year. For...
There were significantly larger declines in BMI and weight in the treated group than controls across all time points among those in whom data were available.
Mean changes in bodyweight from baseline to week 46 were –6.2%, –12.5%, –13.2%, –14.9%, and –2.8%.
In this cross-sectional study of 5229 individuals, prevalence of obesity was highest among people who identified as Asian, Pacific Islander, and White (52.0%).
These findings suggest that sarcopenic obesity may be associated with worse survival, and conducting screening for muscle function may help prevent premature death among older people.
Efficacy and Safety of Once Weekly Semaglutide 2·4 mg for Weight Management in a Predominantly East Asian Population With Overweight or Obesity (STEP 7): a Double-Blind, Multicentre, Randomised Controlled Trial
Source : https://pubmed.ncbi.nlm.nih.gov/38330988/
For the Mandarin, Portuguese and South Korean translations of the abstract see Supplementary Materials section.
At week 44, the proportion of participants who lost 5% or more of their bodyweight was higher in the semaglutide 2.4 mg group than in the placebo group.